Bris­tol My­ers cel­e­brates a big win with FDA ap­proval of $13B car­dio drug mava­camten

Af­ter get­ting hit with an FDA de­lay back in No­vem­ber, Bris­tol My­ers Squibb is fi­nal­ly cel­e­brat­ing a win for mava­camten, the cen­ter­piece of the com­pa­ny’s $13 bil­lion MyoKar­dia buy­out back in 2020.

Reg­u­la­tors ap­proved mava­camten on Thurs­day to treat symp­to­matic ob­struc­tive hy­per­trophic car­diomy­opa­thy, or oHCM: a con­di­tion in which the mus­cu­lar wall be­tween the two bot­tom cham­bers of the heart be­comes thick­er than nor­mal, block­ing blood flow out of the heart.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER